· Intended reorganisation of R&D to increase focus and investment in late-stage development
· Plans to establish centres of excellence in Sweden and Switzerland
· The new focus of the R&D organisation would lead to annual savings of SEK 200–300 M in 2020 to be reallocated to late-stage development. Costs of around SEK 100–200 M relating to the reorganisation and redundancies will be charged in 2019.
Following today’s announcement of the acquisition of emapalumab and related assets, Sobi™ (Swedish Orphan Biovitrum AB (publ) (https://www.sobi.com/en/investors/fda-approves-gamifantr-